Cargando…

Mesothelin expression remodeled the immune-matrix tumor microenvironment predicting the risk of death in patients with malignant pleural mesothelioma

BACKGROUND: The combination of immunobiological agents with immune checkpoint proteins is a promising treatment for malignant pleural mesothelioma (MPM). Mesothelin and anti-PD-L1 antibody-drug conjugates specifically target malignant neoplastic cells, inhibit the migration and invasion of neoplasti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qualiotto, Aline Nery, Baldavira, Camila Machado, Balancin, Marcelo, Ab’Saber, Alexandre, Takagaki, Teresa, Capelozzi, Vera Luiza
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601658/ https://www.ncbi.nlm.nih.gov/pubmed/37901248 http://dx.doi.org/10.3389/fimmu.2023.1268927

Ejemplares similares

The Immunological Landscape of M1 and M2 Macrophages and Their Spatial Distribution in Patients with Malignant Pleural Mesothelioma
por: Laberiano-Fernandez, Caddie, et al.
Publicado: (2023)

Dissecting and Reconstructing Matrix in Malignant Mesothelioma Through Histocell-Histochemistry Gradients for Clinical Applications
por: Balancin, Marcelo Luiz, et al.
Publicado: (2022)

The expression patterns and prognostic significance of pleckstrin homology-like domain family A (PHLDA) in lung cancer and malignant mesothelioma
por: Baldavira, Camila M., et al.
Publicado: (2021)

An integrative histopathologic clustering model based on immuno‐matrix elements to predict the risk of death in malignant mesothelioma
por: Balancin, Marcelo Luiz, et al.
Publicado: (2020)

Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

Modeling extracellular matrix through histo-molecular gradient in NSCLC for clinical decisions
por: Baldavira, Camila Machado, et al.
Publicado: (2022)

In Situ Overexpression of Matricellular Mechanical Proteins Demands Functional Immune Signature and Mitigates Non-Small Cell Lung Cancer Progression
por: Yaegashi, Lygia Bertalha, et al.
Publicado: (2021)

Pulmonary Neuroendocrine Neoplasms Overexpressing Epithelial-Mesenchymal Transition Mechanical Barriers Genes Lack Immune-Suppressive Response and Present an Increased Risk of Metastasis
por: Prieto, Tabatha Gutierrez, et al.
Publicado: (2021)

Level of mesothelin expression can indicate the prognosis of malignant pleural mesothelioma
por: Feng, Feifei, et al.
Publicado: (2020)

Proposing Specific Neuronal Epithelial-to-Mesenchymal Transition Genes as an Ancillary Tool for Differential Diagnosis among Pulmonary Neuroendocrine Neoplasms
por: Prieto, Tabatha Gutierrez, et al.
Publicado: (2022)

A semi-automated microscopic image analysis method for scoring Ki-67 nuclear immunostaining
por: Fernezlian, S.M., et al.
Publicado: (2023)

Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis
por: Tian, Long, et al.
Publicado: (2017)

The Fibrosis-Targeted Collagen/Integrins Gene Profile Predicts Risk of Metastasis in Pulmonary Neuroendocrine Neoplasms
por: Prieto, Tabatha Gutierrez, et al.
Publicado: (2021)

Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis
por: Gao, Ruiyue, et al.
Publicado: (2019)

Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis
por: Cui, Ai, et al.
Publicado: (2014)

Hitting the Bull’s-Eye: Mesothelin’s Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma
por: Yeo, Dannel, et al.
Publicado: (2021)

Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma
por: Sato, Tadashi, et al.
Publicado: (2014)

Clinical outcome of Brazilian patients with non-small cell lung cancer in early stage harboring rare mutations in epidermal growth factor receptor
por: Machado-Rugolo, J., et al.
Publicado: (2023)

Concomitant TP53 mutation in early-stage resected EGFR-mutated non-small cell lung cancer: a narrative approach in a genetically admixed Brazilian cohort
por: Machado-Rugolo, J., et al.
Publicado: (2023)

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
por: Castelletti, Laura, et al.
Publicado: (2021)

Immune Microenvironment and Genetics in Malignant Pleural Mesothelioma
por: Wadowski, Benjamin, et al.
Publicado: (2021)

Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum
por: Creaney, Jenette, et al.
Publicado: (2013)

Hyaluronan and N-ERC/Mesothelin as Key Biomarkers in a Specific Two-Step Model to Predict Pleural Malignant Mesothelioma
por: Mundt, Filip, et al.
Publicado: (2013)

Soluble Mesothelin-Related Peptides Levels in Patients with Malignant Mesothelioma
por: Franko, Alenka, et al.
Publicado: (2012)

MSLN Gene Silencing Has an Anti-Malignant Effect on Cell Lines Overexpressing Mesothelin Deriving from Malignant Pleural Mesothelioma
por: Melaiu, Ombretta, et al.
Publicado: (2014)

Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1
por: Eguchi, Takashi, et al.
Publicado: (2017)

Lymphatic fluctuation in the parenchymal remodeling stage of acute interstitial pneumonia, organizing pneumonia, nonspecific interstitial pneumonia and idiopathic pulmonary fibrosis
por: Parra, E.R., et al.
Publicado: (2012)

Correction: MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma
por: Melaiu, Ombretta, et al.
Publicado: (2017)

Malignant pleural mesothelioma nodules remodel their surroundings to vascularize and grow
por: Kovacs, Ildiko, et al.
Publicado: (2022)

The Impact of Mesothelin in the Ovarian Cancer Tumor Microenvironment
por: Hilliard, Tyvette S.
Publicado: (2018)

The Immune Microenvironment of Malignant Pleural Mesothelioma: A Literature Review
por: Désage, Anne-Laure, et al.
Publicado: (2021)

Prognostic Role of Tumor Immune Microenvironment in Pleural Epithelioid Mesothelioma
por: Ollila, Hely, et al.
Publicado: (2022)

Anti-mesothelin vaccine CRS-207 with or without low-dose cyclophosphamide plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM)
por: Hassan, Raffit, et al.
Publicado: (2015)

Mesothelin Gene Variants Affect Soluble Mesothelin-Related Protein Levels in the Plasma of Asbestos-Exposed Males and Mesothelioma Patients from Germany
por: Rihs, Hans-Peter, et al.
Publicado: (2022)

Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment
por: Zhang, Xianyu, et al.
Publicado: (2022)

A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma
por: de Fonseka, Duneesha, et al.
Publicado: (2018)

Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma
por: Napoli, Francesca, et al.
Publicado: (2021)

Pilot Study to Evaluate Serum Soluble Mesothelin-Related Peptide (SMRP) as Marker for Clinical Monitoring of Pleural Mesothelioma (PM): Correlation with Modified RECIST Score
por: Grosso, Federica, et al.
Publicado: (2021)

Relevance of PD-L1 Non-Coding Polymorphisms on the Prognosis of a Genetically Admixed NSCLC Cohort
por: Machado-Rugolo, Juliana, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cnlofui1ib94hep3qtcg1b1oi7